Read by QxMD icon Read

resveratrol and nafld

Amir Hajighasem, Parvin Farzanegi, Zohreh Mazaheri
CONTEXT: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder. OBJECTIVE: Effects of combined therapy with resveratrol, interval and continuous exercises on oxidative stress, inflammation, and apoptosis in the liver of rats with NAFLD. METHODS: NAFLD rats were organised in patient, saline, resveratrol (RSV), continuous exercise, interval exercise, continuous exercise + RSV, and interval exercise + RSV groups...
February 20, 2018: Archives of Physiology and Biochemistry
Somayyeh Asghari, Mohammad Asghari-Jafarabadi, Mohammad-Hossein Somi, Seyed-Mostafa Ghavami, Maryam Rafraf
OBJECTIVE: There is a promising perspective regarding the potential effect of resveratrol in preventing and treating metabolic disturbances similar to that of calorie restriction. The aim of this study was to evaluate the effects of calorie-restricted (CR) diet on metabolic parameters and then to investigate whether resveratrol supplementation has beneficial effects similar to CR diet in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: This randomized controlled clinical trial was conducted in 90 patients with NAFLD (males and females) aged 20 to 60 years with body mass index (BMI) ranging from 25 to 35 kg/m 2 ...
January 9, 2018: Journal of the American College of Nutrition
Naila Rabbani, Paul J Thornalley
SIGNIFICANCE: Obesity and type 2 diabetes mellitus are increasing globally. There is also increasing associated complications, such as non-alcoholic fatty liver disease (NAFLD) and vascular complications of diabetes. There is currently no licensed treatment for NAFLD and no recent treatments for diabetic complications. New approaches are required, particularly those addressing mechanism-based risk factors for health decline and disease progression. Recent Advances: Dicarbonyl stress is the abnormal accumulation of reactive dicarbonyl metabolites such as methylglyoxal (MG) leading to cell and tissue dysfunction...
January 2, 2018: Antioxidants & Redox Signaling
Yi Guo, Jun-Xiang Li, Tang-You Mao, Wei-Han Zhao, Li-Juan Liu, Yun-Liang Wang
The present study aimed to explore the mechanism of action of Gegen Qinlian decoction (GGQLD) in experimental non-alcoholic fatty liver disease (NAFLD). A total of 30 rats were randomly divided into five groups: The chow, model, high- and low-dose GGQLD (GGQLD-H and GGQLD-L, respectively) and resveratrol (Resl) groups, and were treated with saline, GGQLD and Resl when a model of high-fat diet (HFD)-induced NAFLD was established. Blood lipid and liver enzymes were detected following treatment for 8 weeks and liver tissue pathology was observed using Oil Red O and haematoxylin and eosin staining...
November 2017: Experimental and Therapeutic Medicine
Adi Y Berman, Rachel A Motechin, Maia Y Wiesenfeld, Marina K Holz
Resveratrol is a nutraceutical with several therapeutic effects. It has been shown to mimic effects of caloric restriction, exert anti-inflammatory and anti-oxidative effects, and affect the initiation and progression of many diseases through several mechanisms. While there is a wealth of in vitro and in vivo evidence that resveratrol could be a promising therapeutic agent, clinical trials must confirm its potential. In this work, we reviewed the current clinical data available regarding the pharmacological action of resveratrol...
2017: NPJ Precision Oncology
Qian Liu, Lixin Zhu, Chen Cheng, Yiyang Hu, Qin Feng
Nonalcoholic fatty liver disease (NAFLD) has become more prevalent worldwide. It is often associated with some metabolic diseases, such as obesity, type 2 diabetes, and metabolic syndrome. With increasing focus on the treatment of fatty liver, much attention has been paid to numerous medicinal herbs and dietary substances to provide a new strategy for NAFLD treatment. The natural active compounds from the herbs or diet have been studied as promising treatments for NAFLD. This study aimed to summarize the use and mechanism of action of natural active compounds in the treatment of NAFLD in the recent 10 years...
September 18, 2017: Current Pharmaceutical Design
Shibin Ding, Jinjin Jiang, Guofu Zhang, Yongjun Bu, Guanghui Zhang, Xiangmei Zhao
BACKGROUND: Studies have demonstrated that resveratrol (a natural polyphenol) and caloric restriction activate Sirtuin-1 (SIRT1) and induce autophagy. Furthermore, autophagy is induced by the SIRT1-FoxO signaling pathway and was recently shown to be a critical protective mechanism against non-alcoholic fatty liver disease (NAFLD) development. We aimed to compare the effects of resveratrol and caloric restriction on hepatic lipid metabolism and elucidate the mechanism by which resveratrol supplementation and caloric restriction alleviate hepatosteatosis by examining the molecular interplay between SIRT1 and autophagy...
2017: PloS One
Eman F Khaleel, Ghada A Abdel-Aleem, Dalia G Mostafa
Resveratrol (RES) has the ability to ameliorate nonalcoholic fatty liver disease (NAFLD) and the mechanism remains unclear. Hence, using high-fat diet (HFD) obese rat model, we investigated the effect of a low dose of RES (20 mg/kg) on the hepatic sterol regulatory element-binding protein (SREBPs) - lipogenesis pathway, enzymes involved in β-oxidation and activity of pancreatic lipase. Four groups of rats (n = 8) of control (12% of calories as fat) and HFD (40% of calories as fat) were administered orally with either normal saline as a vehicle or RES as a concomitant treatment for 8 weeks on a daily basis...
February 2018: Canadian Journal of Physiology and Pharmacology
Magdalena Izdebska, Iwona Piątkowska-Chmiel, Agnieszka Korolczuk, Mariola Herbet, Monika Gawrońska-Grzywacz, Renata Gieroba, Marcin Sysa, Klaudia Czajkowska-Bania, Marcelina Cygal, Agnieszka Korga, Jarosław Dudka
Nonalcoholic fatty liver disease (NAFLD) is currently one of the most common chronic liver diseases, especially in developed countries. One group of substances with a potential use in the treatment of NAFLD are plant polyphenols, represented by resveratrol. The aim of this study was to evaluate the effect of resveratrol on steatosis and oxidative stress in HepG2 cells. The steatosis of cells was carried out using free fatty acids: oleic or palmitic acid and their mixtures. Steatosis was visualized using the intracellular lipid staining by Nile Red dye with a fluorescence microscope...
July 31, 2017: Canadian Journal of Physiology and Pharmacology
Alessandra Ferramosca, Mariangela Di Giacomo, Vincenzo Zara
Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver cells. To date, no approved drugs are available for the treatment of NAFLD, despite the fact that it represents a serious and growing clinical problem in the Western world. Identification of the molecular mechanisms leading to NAFLD-related fat accumulation, mitochondrial dysfunction and oxidative balance impairment facilitates the development of specific interventions aimed at preventing the progression of hepatic steatosis...
June 21, 2017: World Journal of Gastroenterology: WJG
Gang Xu, Kaixun Huang, Jun Zhou
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease, is the leading cause of cryptogenic cirrhosis and has consistently been implicated in related metabolic disorders, such as dyslipidemia and type 2 diabetes (T2D). However, the pathogenesis of NAFLD remains to be elucidated, and no established therapeutic regimens for treating NAFLD exist. Adenosine monophosphate (AMP)-activated protein kinase (AMPK), the main cellular energy sensor, has been implicated as a key regulator of hepatic lipid and glucose metabolism...
April 4, 2017: Current Medicinal Chemistry
Cong Liu, Jia-Zhi Liao, Pei-Yuan Li
Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver diseases around the world due to the modern sedentary and food-abundant lifestyle, which is characterized by excessive fat accumulation in the liver related with causes other than alcohol abuse. It is widely acknowledged that insulin resistance, dysfunctional lipid metabolism, endoplasmic reticulum stress, oxidative stress, inflammation, and apoptosis/necrosis may all contribute to NAFLD. Autophagy is a protective self-digestion of intracellular organelles, including lipid droplets (lipophagy), in response to stress to maintain homeostasis...
March 21, 2017: World Journal of Gastroenterology: WJG
Ahmed Elgebaly, Ibrahim A I Radwan, Mohamed M AboElnas, Hamza H Ibrahim, Moutaz F M Eltoomy, Ahmed A Atta, Hend A Mesalam, Alaa A Sayed, Amr A Othman
BACKGROUND: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD. METHODS: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords...
March 2017: Journal of Gastrointestinal and Liver Diseases: JGLD
Qian Chen, Tingting Wang, Jian Li, Sijian Wang, Feng Qiu, Haiyang Yu, Yi Zhang, Tao Wang
As a sugar additive, fructose is widely used in processed foods and beverages. Excessive fructose consumption can cause hepatic steatosis and dyslipidemia, leading to the development of metabolic syndrome. Recent research revealed that fructose-induced nonalcoholic fatty liver disease (NAFLD) is related to several pathological processes, including: (1) augmenting lipogenesis; (2) leading to mitochondrial dysfunction; (3) stimulating the activation of inflammatory pathways; and (4) causing insulin resistance...
January 31, 2017: Nutrients
Tomasz Charytoniuk, Krzysztof Drygalski, Karolina Konstantynowicz-Nowicka, Klaudia Berk, Adrian Chabowski
Nonalcoholic fatty liver disease (NAFLD) is considered to be one of the most common liver pathologies that occur widely among societies with a predominance of the Western dietary pattern. NAFLD may progress from hepatic steatosis to nonalcoholic steatohepatitis (NASH), subsequently leading to cirrhosis and becoming a major cause of hepatocellular carcinoma. Thus its prevention and therapy play an important role in hepatology. To our knowledge, there is no effective treatment for patients with NAFLD. The aim of this review was to summarize the results of recent alternative treatment studies conducted both on cell cultures and in vivo that concern molecular effects of resveratrol (3,5,4'-trihydroxystilbene) in the treatment of NAFLD...
February 2017: Nutrition
Tsuyoshi Chiba, Keiko Noji, Shohei Shinozaki, Sachina Suzuki, Keizo Umegaki, Kentaro Shimokado
OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) is associated with impaired liver function, and resveratrol could suppress NAFLD progression. This study examined the effects of NAFLD on the expression of major cytochrome P450 (CYP) subtypes in the liver and whether the expression could be attenuated by resveratrol. METHODS: C57BL/6 mice (male, 10 weeks of age) were fed a high-fat and high-sucrose (HFHS) diet to induce NAFLD. Major Cyp subtype mRNA expression in the liver was measured by real-time RT-PCR...
December 2016: Journal of Pharmacy and Pharmacology
Yueli Tian, Jingting Ma, Wudong Wang, Lingjuan Zhang, Jia Xu, Kai Wang, Dongfu Li
Nonalcoholic fatty liver disease (NAFLD) is characterized by high levels of nonesterified fatty acids (NEFA), inflammation, and hepatic steatosis. Inflammation plays a crucial role in the development of fatty liver. Resveratrol (RSV) supplement could improve inflammatory response and hepatic steatosis, whereas the underlying mechanism was not well understood. In this study, mice fed with high-fat diet (HFD) exhibited severe hepatic injury and high blood concentrations of the inflammatory cytokines TNF-α, IL-6, and IL-1β...
November 2016: Molecular and Cellular Biochemistry
Chongyang Zhang, Weigang Yuan, Jianguo Fang, Wenqing Wang, Pei He, Jiahui Lei, Chunxu Wang
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with rising prevalence. Increasing evidence has demonstrated that resveratrol, a dietary phytochemical, is capable of attenuating NAFLD development and progression; however, results from clinical studies are inconsistent and inconclusive. Here, we conducted a meta-analysis to evaluate the efficacy of resveratrol on NAFLD, using several parameters to provide new insights for clinical application. We systematically searched EMBASE, PubMed, Science Citation Index, Elsevier, and Cochrane Library databases for studies published up to date (July 2016), in English, to identify and screen eligible, relevant studies...
2016: PloS One
Jung Hee Shin, Ji Hye Jung
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat in the liver despite a low level of alcohol intake, with signs of hepatomegaly. Although in the past, NAFLD was predominantly viewed as an aspect of metabolic syndrome, it is now considered that it should be classified as an independent condition similar to obesity, diabetes, and hypertension. Therefore, new treatment strategies, not based on correcting insulin resistance, are needed for NAFLD. This work analyzes methods of prevention, therapeutic approaches, and mechanisms involved in NAFLD, focusing on the use of flavonoids (epigallocatechin-3-gallate, resveratrol, anthocyanins, and isoflavones) with high antioxidant capacity...
August 18, 2016: Clinics and Research in Hepatology and Gastroenterology
Sara Heebøll, Martin Kreuzfeldt, Stephen Hamilton-Dutoit, Marianne Kjær Poulsen, Hans Stødkilde-Jørgensen, Holger Jon Møller, Niels Jessen, Kasper Thorsen, Ylva Kristina Hellberg, Steen Bønløkke Pedersen, Henning Grønbæk
OBJECTIVE: "The obesity epidemic" has led to an increase in obesity-related conditions including non-alcoholic fatty liver disease (NAFLD), for which effective treatments are in demand. The polyphenol resveratrol prevents the development of experimental NAFLD through modulation of cellular pathways involved in calorie restriction. We aimed to test the hypothesis that resveratrol alleviates NAFLD in a randomised, clinical trial. MATERIALS AND METHODS: A total of 28 overweight patients with transaminasemia and histological NAFLD were randomised 1:1 to placebo or resveratrol 1...
2016: Scandinavian Journal of Gastroenterology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"